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AbstrACt
Introduction Neurogenic claudication due to spinal 
stenosis is common in older adults. The effectiveness of 
conservative interventions is not known. The aim of the 
study is to estimate the clinical and cost-effectiveness 
of a physiotherapist-delivered, combined physical and 
psychological intervention.
Methods and analysis This is a pragmatic, multicentred, 
randomised controlled trial. Participants are randomised 
to a combined physical and psychological intervention 
(Better Outcomes for Older people with Spinal Trouble 
(BOOST) programme) or best practice advice (control). 
Community-dwelling adults, 65 years and over, with 
neurogenic claudication are identified from community and 
secondary care services. Recruitment is supplemented 
using a primary care-based cohort. Participants are 
registered prospectively and randomised in a 2:1 ratio 
(intervention:control) using a web-based service to 
ensure allocation concealment. The target sample size 
is a minimum of 402. The BOOST programme consists 
of an individual assessment and twelve 90 min classes, 
including education and discussion underpinned by 
cognitive behavioural techniques, exercises and walking 
circuit. During and after the classes, participants undertake 
home exercises and there are two support telephone calls 
to promote adherence with the exercises. Best practice 
advice is delivered in one to three individual sessions with 
a physiotherapist. The primary outcome is the Oswestry 
Disability Index at 12 months. Secondary outcomes 
include the 6 Minute Walk Test, Short Physical Performance 
Battery, Fear Avoidance Beliefs Questionnaire and Gait 
Self-Efficacy Scale. Outcomes are measured at 6 and 
12 months by researchers who are masked to treatment 
allocation. The primary statistical analysis will be by 
‘intention to treat’. There is a parallel health economic 
evaluation and qualitative study.
Ethics and dissemination Ethical approval was given on 3 
March 2016 (National Research Ethics Committee number: 
16/LO/0349). This protocol adheres to the Standard Protocol 
Items: Recommendations for Interventional Trials checklist. 
The results will be reported at conferences and in peer-
reviewed publications using the Consolidated Standards of 
Reporting Trials guidelines. A plain English summary will be 
published on the BOOST website.
trial registration number ISRCTN12698674; Pre-results. 
IntroduCtIon  
Neurogenic claudication (NC) is a condi-
tion that frequently affects older adults.1 The 
strengths and limitations of this study
 ► The BOOST (Better Outcomes for Older people 
with  Spinal Trouble) Trial is a large, multicentred, 
randomised controlled trial with a prespecified sam-
ple size estimate and includes health economic and 
qualitative evaluations.
 ► The primary outcome is the Oswestry Disability 
Index, but we also collect a range of secondary 
outcomes including objective physical capacity 
measures and self-reported pain, symptoms and 
mobility, which are highly relevant to this patient 
group.
 ► The intervention is individually tailored and uses 
group supervision to maximise the potential for 
cost-effectiveness.
 ► Due to the nature of the intervention, participants 
cannot be blinded to treatment allocation.
 ► At some sites, the same physiotherapist is delivering 
both trial interventions, but treatments are delivered 
according to a manualised protocol and quality con-
trol visits are conducted to reduce the risk of intro-
ducing bias to the trial.
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burden of symptoms is substantial. NC presents as pain, 
discomfort or other symptoms radiating from the spine 
into the buttocks and legs, which are provoked by walking 
or prolonged standing and relieved by sitting or lumbar 
flexion.2 Other signs and symptoms include weakness, 
altered sensation, fatigue and gait changes.2 Pain in the 
lower back is usual but not a necessary diagnostic feature. 
The symptoms of NC are thought to arise from pressure 
on the nerves and blood vessels in the spinal canal caused 
by degenerative changes narrowing the volume of the 
spinal canal. Narrowing may or may not be evident on 
radiological imaging.2 3 When narrowing is evident radio-
logically, the condition is termed lumbar spinal stenosis 
(LSS). The relationship between imaging results and 
symptoms is inconsistent as not all people with radiolog-
ical narrowing report symptoms of NC.2 3
Symptoms due to spinal stenosis are the most common 
reason for spinal surgery in people over 65 years of age.4 
However, the effectiveness of surgery is unclear, and it 
exposes older people to considerable risk of complica-
tions, including wound infection and cardiorespiratory 
problems.4–6 Surgery is also expensive. Current clin-
ical guidelines suggest that physiotherapy is an option 
for patients with symptoms arising from LSS before 
proceeding to surgery.7 However, we do not know 
whether physiotherapy is effective, nor which physio-
therapy techniques should be used.8 A Cochrane system-
atic literature review reports that the current evidence 
for non-operative care for people with NC is very low to 
low quality.9 All recent reviews agree that higher quality 
trials are needed.9–13 Despite NC being a condition associ-
ated with older age, interventions tested to date have not 
targeted age-associated changes in the musculoskeletal 
system of participants (such as generalised sarcopenia 
and frailty) or the psychological impact of pain. In order 
to generate high-quality evidence regarding non-surgical 
care for NC, our aim is to conduct a high-quality, multi-
centred, randomised controlled trial (RCT) of a physio-
therapist-delivered, combined physical and psychological 
intervention.
objECtIvEs
The following are the objectives:
 ► To estimate the clinical and cost-effectiveness of a 
physiotherapist-delivered, combined physical and 
psychological intervention for older adults with NC 
compared with best practice advice.
 ► To explore whether indicators of frailty, behavioural 
factors and radiological (MRI) biomarkers can iden-
tify groups of participants who are more likely to 
respond positively to the intervention using prespeci-
fied subgroup analyses.
 ► To conduct a parallel, longitudinal qualitative study 
with a sample of trial participants to better understand 
participant experiences of living and ageing with NC, 
and to inform implementation if the intervention is 
successful.
MEthods/dEsIgn
overview
The study design is a multicentred RCT with embedded 
qualitative study and economic evaluation (see figure 1).
We are currently recruiting community-dwelling 
older adults with symptoms of NC. Recruitment opened 
on 25 July 2016 and we anticipate recruitment to be 
completed around June 2018. Participants are identified 
from National Health Service (NHS) physiotherapy and 
consultant spinal clinics in community and secondary 
care settings. In addition, participants are identified 
through a primary care-based cohort study (the Oxford 
Pain, Activity and Lifestyle (OPAL) cohort study). The 
OPAL cohort study is being conducted in the same local-
ities as the trial.
The experimental intervention is a physiotherapist-de-
livered, combined physical and psychological programme. 
Participants attend an individual session, followed by 12 
group sessions delivered over a 12-week period. During 
the individual session, participants undergo an assessment 
and are prescribed the exercises they will carry out during 
the group sessions tailored to their ability, symptom 
presentation and general health. The group sessions 
consist of (1) education and group discussion based on 
cognitive behavioural (CB) techniques; (2) warm-up and 
circuit exercises; and (3) a walking circuit. The educa-
tion component focuses on pain management strategies, 
engagement with home exercises and increasing physical 
activity. The exercises target muscle strength, balance 
and flexibility, while the walking circuit aims to increase 
walking self-efficacy and mobility. The education compo-
nent and supervised exercise are provided in groups of 
approximately six participants to maximise the potential 
for cost-effectiveness. There are two follow-up phone calls 
on completion of the group sessions to encourage adher-
ence with the home exercise programme.
The comparator is advice given by a physiotherapist 
(best practice advice), ideally in one session, but up to two 
further review sessions are permissible. Advice includes 
self-management strategies, home exercises and encour-
agement to increase physical activity.
Participants are randomised in a 2:1 ratio (interven-
tion:control) and followed up for 12 months (primary 
endpoint).
Eligibility
Participants are included in the trial if they fulfil the eligi-
bility criteria listed in box 1. In the UK, the majority of 
adults are registered with a primary care practice. Due 
to the pragmatic nature of this trial, we include people 
with symptoms consistent with the clinical presentation 
of NC rather than a diagnosis of spinal stenosis based on 
evidence of narrowing of the spinal canal on an MRI scan. 
NC presents as a cluster of symptoms easily recognised 
using simple self-report questions identified in a recent 
systematic literature review3 (table 1). These questions 
have excellent sensitivity and specificity for identifying 
NC3 and are used to screen for eligible participants.
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The exclusion criteria are largely related to the partic-
ipant being unable to participate in the intervention, 
for example, if they are unable to follow instructions or 
mobilise short distances without assistance. Participants 
are not excluded on the basis of any existing comorbidi-
ties unless their general practitioner (GP) feels inclusion 
in the study places them at risk.
Approach
Potential participants are approached via two routes:
Physiotherapy and consultant spinal clinics in community and 
secondary care NHS settings
Potential participants are identified by clinical staff in 
physiotherapy and consultant spinal clinics or from 
referrals. Staff are asked to identify potentially eligible 
patients based on age (≥65 years) and symptoms (back 
and/or leg symptoms) and to screen out those on surgical 
waiting lists if that information is available. Clinical staff 
approach potentially eligible patients attending clinics, 
provide information about the study and ask if they are 
interested in being contacted by the research team. Clin-
ical staff may also contact new referrals by telephone to 
inform them about the study. Potential participants who 
are interested and willing to be contacted by the research 
team are provided with a participant information leaflet 
(PIL), and their contact details are passed to the BOOST 
(Better Outcomes for Older people with Spinal Trouble) 
researcher for full eligibility screening.
Figure 1 Study flow chart. BOOST, Better Outcomes for Older people with Spinal Trouble; NHS, National Health Service; 
OPAL, Oxford Pain, Activity and Lifestyle; RCT, randomised controlled trial.
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The OPAL cohort study
The OPAL cohort study is a population-based cohort 
study. Participants are identified from a random sample 
of patients aged over 65 years registered with each partic-
ipating primary care practice. The OPAL cohort study is 
currently ongoing at 34 primary care practices, and will 
be described elsewhere.
Embedded within the cohort study postal question-
naires are self-report questions to identify individuals with 
possible NC (box 1). During the process of consent for 
the cohort study, OPAL participants are asked for addi-
tional consent for the University of Oxford to provide 
information and an invitation to clinical trials relevant 
to their clinical profile. OPAL participants who fulfil the 
initial criteria for the BOOST Trial (table 1) are invited to 
take part in eligibility screening for the trial and provided 
with the BOOST PIL. OPAL participants who accept the 
invitation for screening are then contacted by telephone 
for initial screening.
Eligibility screening
Potential participants identified via NHS spinal 
clinics or the OPAL cohort study are telephoned by 
the BOOST researcher (physiotherapists or research 
nurses) working at each site. During this telephone 
call, the researcher provides further information about 
the trial and completes initial eligibility checks. Eligible 
patients are invited to attend a research clinic appoint-
ment for a full assessment. If an individual requests to 
undertake the initial eligibility check in person, then 
this is arranged.
The research clinic appointment includes assessment 
of symptoms to ensure they are consistent with NC (using 
the questions in table 1), and screening for cauda equina 
syndrome or signs of serious pathology requiring imme-
diate referral for investigations. Potential participants 
also undertake the Abbreviated Mental Test (AMT)14 to 
screen for cognitive impairment, which would make it 
difficult for a person to participate in the intervention. 
The AMT contains 10 items to assess orientation, regis-
tration, recall and concentration. This test can be used 
by any clinician and only takes 3–4 minutes to admin-
ister.15 A score of 6 or below (out of 10) suggests cognitive 
impairment requiring further assessment and patients 
are advised to consult their GP.15–17 A mobility assessment 
is undertaken if required to ensure the participant is able 
to mobilise independently at least 3 m unassisted (with or 
without a walking aid).
Informed consent
On completion of the full eligibility assessment, eligible 
participants are asked to provide written informed 
consent prior to enrolling them into the trial. The consent 
is taken by a researcher who has completed training in 
the consent procedures for the BOOST Trial.
box 1 Eligibility criteria
Inclusion criteria.
 ► Registered with a primary care practice.
 ► 65 years and over.
 ► Participant is willing and able to give informed consent for participa-
tion in the randomised controlled trial.
 ► Reports symptoms consistent with neurogenic claudication.
Exclusion criteria.
 ► Living in a residential care or nursing home.
 ► Has a terminal condition with a life expectancy of less than 6 months.
 ►  Any substantial health or social concern that, in the opinion of the 
patient’s general practitioner, would place the patient at increased 
risk or inability to participate, including known inability to provide 
informed consent, for example, dementia.
 ► Unable to walk 3  m (width of a small room) without the help of 
another person.
 ► On a surgical waiting list.
 ► Presents with cauda equina syndrome or signs of serious pathology 
requiring immediate referral for investigations.
 ► Cognitive impairment (defined as an Abbreviated Mental Test score 
of 6 or less).
 ► Registered blind.
 ► Unable to follow verbal instructions, which would make participation 
in the experimental treatment arm of the trial impractical, for rea-
sons including severe hearing impairment not corrected by a hear-
ing aid or inability to follow simple safety instructions (eg, English 
comprehension).
Table 1 Screening questions from the OPAL cohort study questionnaire3
Questions
Response required to be eligible for 
BOOST Trial
1.  In the past 6 WEEKS, have you had back pain and/or pain or other symptoms 
such as tingling, numbness or heaviness that travelled from your back into 
your buttocks or legs?
(Note: If the answer to this question is no, then the participant will not complete 
the remaining questions).
Yes.
1. Does standing make the pain or symptoms in your buttocks or legs worse?
2. Does walking make the pain or symptoms in your buttocks or legs worse?
3. Does sitting down make the pain or symptoms in your buttocks or legs better?
4. Does bending forward (eg, to push a shopping trolley) make the pain or 
symptoms in your buttocks or legs better?
Yes to at least one of these questions.
BOOST, Better Outcomes for Older people with Spinal Trouble; OPAL, Oxford Pain, Activity and Lifestyle.
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baseline assessment
After providing consent, the participant then completes 
a baseline questionnaire and undergoes a clinical assess-
ment by the researcher. Data collection is described in 
table 2. There are a number of variables only collected 
at baseline for the purposes of providing descriptive data 
on the sample. The participant is weighed using digital 
scales wearing light, indoor clothing with their shoes 
removed. Weight is recorded to the nearest 0.1 kg. Height 
is measured using a stadiometer positioned against a wall. 
The participant stands on the platform, shoes removed, 
as upright as possible, hands by their side. The head plate 
of the stadiometer is lowered until it gently rests on the 
top of the participant’s head and the height is recorded 
in metres from the measuring rod, to the nearest 0.001 m 
(1 mm).
The participant provides self-reported data including 
the demographic variables listed in table 2, comorbidi-
ties including other pain problems (measured using 
the Nordic Pain Questionnaire18 19) and their current 
mobility status. Measures of mobility status include use 
of walking aids inside and outside, and self-rated walking 
speed.20 Change in mobility in the last year is measured 
using a 5-point scale constructed for the trial.
The STarT Back Screening Questionnaire21 is 
completed, allowing participants to be categorised 
according to their risk (low, medium or high) of devel-
oping persistent, disabling symptoms.21 Self-reported 
psychological factors with a potential impact on outcome 
are also collected. These include their confidence to 
exercise (Exercise Self-Efficacy Scale (short version)22) 
and their intention to carry out their home exercises 
using a question constructed for the trial (see table 2). 
Participants’ attitudes to the physical changes associated 
with ageing are measured using the Attitudes to Aging 
Questionnaire—physical changes subscale.23
Variables collected at follow-up are described in the 
Outcome measures section.
Imaging
Alongside the RCT, there is an exploration of whether 
MRI scan parameters along with other baseline factors 
moderate response to physiotherapy treatment. Indirect 
visualisation by MRI is the gold standard for diagnosing 
LSS when a patient presents with NC, and is always under-
taken before surgery, but not necessarily before conser-
vative treatment. Increasingly, GPs have open access to 
MRI, and if MRI were predictive of response to conser-
vative treatment this could aid GPs’ clinical decision 
making. Despite the expense, there is remarkably little 
evidence about whether MRI scans can guide treatment 
choice effectively. Research evidence indicates that the 
fit between symptoms and MRI changes is poor.24 25 As 
MRI is currently the most common imaging investigation 
used, MRI data will be collected for all participants and 
we will systematically quantify the imaging characteris-
tics. Pre-existing scans, taken in the 12 months preceding 
randomisation, will be used where possible to reduce the 
need for scanning.
Participants will be referred for an MRI study of the 
lumbar spine if they have not had one in the 12 months 
prior to randomisation. For these participants, the MRI 
scan will be taken after completion of other baseline data 
collection, and where possible before randomisation. 
Due to the nature of spinal stenosis, we would not expect 
spinal parameters to change markedly over a year-long 
period, hence the rationale for including existing scans. 
Practically, it is not possible to collect all MRI data prebase-
line data collection as this may delay treatment and create 
unacceptable waiting times. For the subset of people who 
have MRI scans prior to randomisation, we will undertake 
formal subgroup analysis. We will explore other aspects of 
the relationship between functional outcomes and scan 
characteristics in additional analyses (not to be reported 
alongside the main trial results).
Consent for referral for a new MRI or use of an existing 
scan is obtained at the time of consent for the trial. 
Existing scans are transferred to a central repository for 
analysis in DICOM (Digital Imaging and Communica-
tions in Medicine) format.
The MRI data collection follows the protocol typical 
of NHS imaging departments. This is very similar across 
departments and efforts have been made to standardise 
the protocol where significant differences were identified.
We anticipate that a small number of participants will 
not have an MRI scan due to contraindications or by 
personal choice. Lack of an MRI scan does not exclude 
participants from the trial.
Imaging protocol
The MRI scan is performed supine, with the knees 
supported in flexion by a small foam wedge, resulting 
in relaxation of the normal lumbar lordosis. Imaging is 
performed using a dedicated spine phased array coil.
T1-weighted and T2-weighted sagittal imaging is 
followed by T2-weighted axial imaging of at least the 
lower three discs. The axial imaging is either taken as 
three separate blocks, each angulated and entered on the 
discs, or as a single block extending from L3 to S1.
Imaging parameters should be near those described in 
table 3. The BOOST Trial radiologist liaises with site to 
ensure data scans are suitable for data collection.
MRI scans are assessed by a single observer blinded to 
treatment allocation. Measurement of bony canal and 
dural sac cross-sectional area at each vertebral level allows 
assessment of central canal stenosis. The size of the lateral 
recess and neural exit foramen is measured and recorded 
quantitatively. The exact degree of narrowing to confirm 
stenosis is not well defined. In a review by Steurer et al,26 
a dural sac cross-sectional area of less than 100 mm2 was 
considered diagnostic of central canal stenosis. Similarly, 
lateral recess depth and foraminal diameter measure-
ments of less than 3 mm have been considered diagnostic 
of lateral recess and foraminal stenosis, respectively.
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Provision of MRI results to participants
MRI scans requested for the purpose of the trial and not 
as part of a participant’s clinical management are research 
investigations only. These are collected and assessed by the 
trial radiologist. If a serious spinal pathology is identified, 
the participant’s GP and/or spinal consultant are imme-
diately informed. If no serious pathology is identified, 
then scan results will be made available to participants at 
the end of the study if requested. MRI reports will be sent 
to each participant’s GP or spinal consultant so that scan 
results are explained to the participant appropriately.
randomisation and masking
Following baseline data collection, the researcher uses 
a web-based service to randomise the participants. 
During this process, the researcher is not informed of 
the treatment allocation. Instead, an automated email 
is sent directly to the physiotherapists who provide the 
interventions.
The web-based randomisation service is provided by 
the Oxford Clinical Trials Research Unit consistent with 
UK Clinical Research Collaboration (UKCRC) approved 
standard operating procedures, ensuring prospective 
registration and allocation concealment. Randomisation 
is stratified by centre, age (65–74 years and 75+ years) and 
gender. Participants are randomised in a 2:1 ratio (inter-
vention:control) to ensure that there are enough partic-
ipants to run a group intervention and minimise waiting 
times.
Physiotherapists delivering the interventions and 
participants cannot be masked to treatment allocation. 
All participants receive an initial 1-hour appointment. 
For those randomised to the BOOST programme, this is 
an assessment prior to attending the group sessions. For 
those randomised to the control arm, it is their initial 
physiotherapy session to deliver best practice advice. 
During this appointment, participants are informed 
of their treatment allocation by the physiotherapist. To 
ensure that researchers collecting follow-up data remain 
masked to treatment allocation, physiotherapists and 
participants are asked not to share information about 
treatment allocation with researchers.
The trial statistician and the research staff undertaking 
quality assurance checks and the qualitative study are not 
blinded to treatment allocation. The remaining members 
of the trial management team, including all those who 
are involved in data management, are masked to treat-
ment allocation.
outcome measures
Follow-up data are collected at 6 and 12 months after 
randomisation, at a clinic appointment. The outcomes 
are listed in table 2.
Primary outcome
The primary outcome is low back pain disability measured 
using the Oswestry Disability Index (ODI V.2.1a)27 28 at 
12 months after randomisation. The ODI is quite widely M
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used as a measure for NC and very widely used in the field 
of back pain. A comparison of the psychometric proper-
ties of four of the most promising self-report measures 
for NC demonstrated that the ODI had superior prop-
erties to other measures.27 It is highly applicable to NC 
because it includes items on standing and walking. Scores 
range from 0 to 100, with higher scores indicating greater 
disability. Participants are asked to consider back and leg 
symptoms when responding, including discomfort, heavi-
ness, aching, tingling and numbness. Responses are not 
limited to the impact of back pain only.
Secondary outcomes
A range of self-reported and physical measures are 
collected to evaluate the impact of the intervention on 
key treatment targets (symptoms of NC, mobility, physical 
activity, strength, balance, frailty and falls, and cognitive 
and behavioural factors related to adherence with exer-
cise and improving physical activity levels).
self-reported measures
Self-reported measures related to symptoms and their 
impact include the Swiss Spinal Stenosis Questionnaire,27 
Global Rating of Change,29 satisfaction with treatment 
using a 5-point scale constructed for the trial, health-re-
lated quality of life measured using the Euroquol 5 
Dimension 5 Level Scale (EQ-5D-5L),30 and how well 
participants are managing their leg and back symptoms 
on a 10-point scale constructed for the trial.
Information is collected about cognitive and 
behavioural factors targeted during the intervention that 
are hypothesised to mediate the effects of the interven-
tion. Fear avoidance is measured using the Fear Avoidance 
Beliefs Questionnaire.31 Self-efficacy is measured from 
different perspectives. Participants rate their confidence 
to walk half a mile using a single item from the Modified 
Gait Self-Efficacy Scale.32 To understand maintenance of 
exercise and physical activity, drawing on theoretical and 
empirical literature on this topic,33 participants also rate 
their confidence to restart their exercises having stopped 
them (self-efficacy recovery33 34) and their confidence to 
maintain their exercises in the long term (self-efficacy 
maintenance33 34). Measures related to the adherence 
of exercises and increasing physical activity are collected 
using the Index of Habit,35 self-reported frequency of 
exercise and satisfaction with their attempts to increase 
their physical activity36 measured on a 5-point scale 
constructed for the trial. Change in mobility in the last 
6 months is measured using a 5-point scale constructed 
for the trial.
A range of measures are collected to capture constructs 
related to ageing. Frailty is measured using the Tilburg 
Frailty Index,37 and information about falls and fall-re-
lated injuries is collected as recommended by the Preven-
tion of Falls Network Europe.38 Health resource use will 
be collected using the Client Service Receipt Inventory.39
Physical assessment
A measure of postural alignment is undertaken to quan-
tify the degree of thoracic kyphosis.40 41 The participant 
removes their shoes and socks and stands as upright as 
possible, with their sacrum and back against the wall, 
with hands by their sides. The researcher measures 
the distance from the spinous process of the seventh 
cervical vertebrae to the wall using a ruler. It is an alter-
native to the occiput to wall measurement, but reflects 
kyphosis better as it minimises error due to head posi-
tion.40 41
We then collect measures related to mobility, balance 
and strength, which are important targets of the interven-
tion and markers related to ageing and frailty.
The Short Physical Performance Battery (SPPB)42 
measures three aspects of physical performance: standing 
balance, walking speed and the time taken to perform 
five chair stands. An overall score is given by adding the 
scores for each test. Researchers follow published guid-
ance on the test which is, briefly, as follows42:
Standing balance
Standing balance is rated on a scale of 0–4 according to 
the participant’s ability to maintain three test positions 
(side-by-side stance, semitandem and full tandem) for 
10 s.
Walking speed
Walking speed is measured on an eight-feet long walking 
course with no obstructions for a further two feet at each 
end. The participant is instructed to ‘Walk to the other 
end of the course at your usual speed, just as if you were 
walking down the street to go to the shop’. The time 
taken for the participant to walk between the two markers 
is recorded to the nearest 0.1 s. The test is carried out 
twice and the faster of the two times is used to score the 
test on a scale of 0–4.
Table 3 Imaging parameters
Sequ FOV Slice Gap TR TE ETL Phase Freq Nex
T2 sagittal 370 13/4 1 4061 102 23 320 512 3
T1 sagittal 370 13/4 1 446 11 23 224 416 3
T2 axial 200 30/4 1 4955 111 25 224 320 3
ETL, echo train length; FOV, Field of view; Freq, Frequency; Nex, Number of excitations; Sequ, Sequence; TE, time to echo; TR, Time to 
repeat.
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Chair stands
The participant sits in a straight-backed chair with 
their arms folded across their chest. They are given the 
following instructions: ‘Now stand up straight 5 times in 
succession, as fast as you can’. The time taken to perform 
the five chair stands (from the initial sitting position to 
the final standing position at the end of the fifth stand) is 
used to score the test on a scale of 0–4. If the participant 
is unable to complete the test, then they are given a score 
of 0.
The 6 Minute Walk Test (6MWT)43 measures the 
distance that the participant is able to walk in 6 minutes. 
The researcher marks out an indoor walking course which 
is flat and straight and marked with cones at each end. 
The length of the test track is standardised at each site to 
ensure that the follow-up assessments are carried out on 
the same length test track. The recommended length of 
the course is a minimum of 10 m in total, but it is depen-
dent on the space available at each site.
One lap consists of walking to the turnaround point of 
the course and returning to the start point. All researchers 
were provided with a 6MWT compact disc which is played 
during the test and counts down the 6 minutes of the 
walking test while the researcher counts the number of 
laps with a lap counter.
Prior to starting the test, the researcher also asks the 
participant if they have symptoms of NC. If they do not 
have any symptoms when starting, the participant is asked 
to verbally indicate if they begin to experience symptoms 
during the test. The distance at which their symptoms 
begin is recorded by the researcher.
The researcher measures the participant’s hand grip 
strength44 using a Jamar Plus+ Dynamometer and follows 
the protocol outlined by Roberts et al.45 The participant 
is seated in a chair with arms, with their hips, knees and 
ankles at 90°, and their feet flat on the ground. The 
participant’s arm is supported on the armrest with their 
wrists level with the end of the armrest. During the test 
the researcher supports the weight of the dynamom-
eter. Using standardised instructions, the participant is 
instructed to squeeze the handle of the dynamometer 
until they reach a maximal contraction and hold for 
5 seconds. The procedure is repeated on the other side. 
Three measurements are taken on each hand allowing 
at least 30 seconds rest between measurements on the 
same hand. The highest reading is used as the summary 
measure.
Follow-up procedures
All participants are invited to attend a face-to face clinic 
appointment at 6 and 12 months. This is arranged by 
the researcher at each site. However, if a participant is 
unable to attend the clinic appointment, they are mailed 
a questionnaire that contains the primary outcome, all 
self-reported items and a participant completed version 
of the Client Service Receipt Inventory, but excludes the 
physical assessment. If the questionnaire is not returned 
within 2 weeks, then a second copy of the questionnaire is 
sent by the BOOST Trial Office as a reminder. If this is not 
returned within a further 2 weeks, then the BOOST Trial 
Office carries out a reminder phone call. After another 
2 weeks, if the questionnaire has not been returned, then 
the BOOST Trial Office will attempt to contact the partic-
ipant by telephone and collect core outcomes consisting 
of the primary outcome (ODI), pain troublesomeness 
rating, whether they are on a waiting list for spinal surgery, 
EQ-5D-5L, self-rated walking ability, falls and falls-related 
fractures, self-reported exercise adherence, and a brief 
version of the Client Service Receipt Inventory.
Adverse events
A safety reporting protocol has been developed to 
manage the reporting of related and unexpected serious 
adverse events (SAEs) and directly attributable adverse 
events (AEs). An AE is any untoward medical occurrence 
in a participant during a trial. There may or may not 
be a causal relationship with the trial intervention. AEs 
may be identified by the physiotherapists delivering the 
trial treatments or by researchers conducting follow-up 
assessments who have been trained in reporting proce-
dures. SAEs must be reported to the trial management 
team within 24 hours of the physiotherapist or researcher 
becoming aware of the event. The Chief Investigator 
determines whether AEs require reporting to the Ethics 
Committee, Data Monitoring and Ethics Committee 
(DMEC) and Trial Sponsor.
training and quality assurance of the research protocol
Researchers undergo approximately 4 hours of training 
covering eligibility screening, consent taking and data 
collection. They are provided with a manual containing 
detailed instructions for all trial procedures. All 
researchers undergo a quality assurance check to ensure 
they are following the trial protocol. This involves a 
BOOST team member observing the researcher carrying 
out the eligibility screening, taking consent and collecting 
trial data. Trial paperwork is checked for completeness. 
If any deviations from the protocol are identified, then 
further training is provided.
study interventions
Control intervention: best practice advice
The control intervention is best practice advice which is 
delivered in a one-to-one session with a physiotherapist. 
Participants attend an initial appointment of up to 1 hour 
consisting of an assessment followed by the provision of 
advice and education. Advice and education includes 
education about NC, being physically active, use of 
medications, when to seek more advice and prescription 
of a home exercise programme (up to four exercises). 
Flexion and trunk stabilisations are recommended, but 
the physiotherapist may prescribe other exercises based 
on their assessment, if required. The physiotherapist may 
prescribe a walking aid if the assessment indicates (eg, to 
improve walking by increasing stability or for pain relief). 
Participants are provided with written information. 
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Ideally, the control intervention should be delivered in 
one session. A maximum of two half-hour review appoint-
ments is permitted. During these sessions they can 
re-enforce verbal advice given, and review walking aids 
or exercises provided in the initial session, but are not 
permitted to provide treatments such as manual therapy, 
electrotherapy, acupuncture, hydrotherapy or structured 
exercise sessions.
The content of the control intervention has been 
informed by a survey of current physiotherapy prac-
tice46 and through consultation with clinicians and 
patient representatives. Physiotherapy provision in the 
NHS is variable for this patient group. Many patients 
are not referred for physiotherapy, some receive advice 
on self-management at physiotherapy spinal clinics and 
some receive a course of physiotherapy comprising advice 
and exercises. Comer et al8 compared a single advice and 
education session with up to six sessions of standard phys-
iotherapy and showed no difference in outcomes. We 
recommend that the majority of participants receive one 
session of advice and education as no additional benefit 
has been demonstrated from extra sessions of standard 
physiotherapy. However, there are situations where the 
treating physiotherapist will feel that a review appoint-
ment is necessary (eg, if they have provided a walking aid 
and need to review its use) so this is permissible and we 
felt broadly reflected usual care in the NHS.
Experimental intervention: the BOOST programme
The BOOST programme will be described in full 
according to the Template for Intervention Description 
and Replication guidance47 elsewhere, including the 
rationale and development. A brief summary is provided 
here.
Participants are invited to attend twelve 90 minute 
group sessions over a 12-week period. We recommend that 
one physiotherapist delivers the BOOST programme to a 
group of six participants. If larger groups are conducted, 
then a physiotherapy assistant or another physiothera-
pist may be required. Prior to attending the programme, 
each participant attends an individual appointment (up 
to 1 hour) for an assessment and to set their individual-
ised exercise and walking circuit targets for the group 
sessions. The baseline target for the strengthening exer-
cise is tailored to each participant by varying the number 
of repetitions and sets, and the addition of weights as 
applicable.
Each session follows the same format. Participants take 
part in an education and discussion session, facilitated 
by the physiotherapist (30 minutes) and incorporating 
behavioural change strategies to encourage adherence 
with home exercises. This is followed by the exercise 
programme lasting approximately 1 hour. There is a short 
warm-up of seated exercises performed as a group, which 
includes arm raises, trunk rotation, pelvic tilting and knee 
lifts. Then participants undertake a circuit of strength-
ening (sitting knee extension, sit to stand, standing hip 
abduction and standing hip extension), stretching (a 
combined hip flexor and calf stretch) and a balance 
exercise.48 49 Each participant undertakes their individ-
ually tailored programme, which is progressed over the 
12 weeks. The strengthening exercises are progressed by 
increasing the number of repetitions and sets, increasing 
the load or adding speed. The final part of the exer-
cise element is a supervised walking circuit, designed 
to improve walking ability and fitness,48 which is also 
progressed over the 12 weeks by increasing the distance 
walked, increasing walking speed, adding balance chal-
lenges such as stairs or obstacles, or adding weights. The 
exercises carried out during the supervised sessions make 
up the home exercise programme (warm-up, exercise 
circuit and walking).
Participants attend the supervised sessions twice a 
week for sessions 1–6. As they progress through the 
programme, attendance becomes less frequent (weekly 
for sessions 7–9, then fortnightly for sessions 10–12). The 
home exercise programme is introduced during session 5 
so that participants begin to undertake their home exer-
cise programme while supported by the physiotherapist. 
On completion of the 12 group sessions, participants are 
asked to carry out their home exercise programme at 
least twice per week so that it becomes a habitual activity.
The physiotherapist monitors progress during the 
programme by asking participants to rate how well they 
feel they are managing their condition (0–10 Numer-
ical Rating Scale) and how their symptoms are affecting 
walking (walking item from the ODI) at the pregroup 
assessment, and at sessions 3, 6, 9 and 12. At the end of 
the 12-week programme, the physiotherapist carries out 
two follow-up telephone reviews with each participant 
to promote long-term adherence with the home exer-
cise programme. These take place approximately 1 and 
2 months after completing the supervised sessions, and 
take approximately 15 minutes each.
Concomitant care
Participants may seek other forms of treatment during 
the trial if they feel it is necessary. Additional treatments 
accessed by participants, including contact with their GP 
or other health professionals, will be recorded on the 
Client Service Receipt Inventory39 at follow-up.
Physiotherapist training and quality assurance of intervention 
delivery
The interventions are delivered by physiotherapists regis-
tered with the Health and Care Professions Council. 
All physiotherapists delivering the BOOST programme 
attend a 1-day training course, are provided with an inter-
vention manual and undertake 3 hours of online training. 
All physiotherapists delivering the control intervention 
attend 3 hours of training and are provided with an inter-
vention manual. At some sites, the same physiotherapist 
delivers both arms of the trial. Both interventions are 
delivered according to a manualised protocol to reduce 
the risk of introducing bias to the study, and routine 
quality assurance checks are conducted. Visits are made 
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to each site and at least one session of each intervention 
is observed. Feedback is provided to the physiotherapist 
on completion of the session and any issues or training 
needs identified. Another visit is arranged if substantial 
concerns are identified.
A structured checklist is used to monitor intervention 
delivery and ensure that all elements of the interventions 
are delivered as intended. We developed the education 
and discussion session of the BOOST programme with 
the assistance of a CB therapist who also assisted with 
training. The CB therapist helped to develop the check-
list for the BOOST programme to ensure all the neces-
sary components of the education and discussion section 
of the session were covered. The checklist is completed 
during the observed session. The education and discus-
sion session may also be assessed via recording (depending 
on resources and BOOST staff capacity). All participants 
provide consent for sessions to be recorded for quality 
assurance purposes when they enrol in the study, and we 
seek verbal consent from the physiotherapist.
Following initial quality assurance checks and feed-
back, we also undertake fidelity assessments of both 
interventions that are not fed back to the physiothera-
pists. Feedback at this stage is not provided as we need to 
understand how this intervention would be delivered in 
the clinical setting if it were to be implemented.
A structured record of the interventions (treatment 
log) is completed by the physiotherapists and used to 
monitor fidelity. We collect attendance rates to monitor 
adherence with the interventions. Additional site visits 
will be conducted if any problems with intervention 
delivery are identified.
sample size
At 80% power and 5% two-sided significance levels, the 
proposed sample size is 321 participants in total providing 
data at 12-month follow-up (214 in the intervention arm 
and 107 in the control arm), after which inflation for 
potential loss to follow-up (20%) yields an overall target of 
402 (268 intervention, 134 control). If power is increased 
to 90%, then a sample size of 429 (286 in the intervention 
arm and 143 in the control arm) is required, after which 
inflation for potential loss to follow-up (20%) yields an 
overall target of 540 (360 intervention, 180 control).
These calculations have been based on the assumption 
that a between-group difference of five points is consid-
ered clinically significant on the ODI, with a baseline SD 
of 15, consistent with published estimates in older popu-
lations and those with NC.50 51 This yields a standardised 
difference of 0.33, a moderate effect size, which is consis-
tent with being a reasonable target for a pragmatic trial.52
The loss to follow-up of 20% has been based on recent 
experiences of rehabilitation trials in older adults.53 We 
estimate that the therapist effects will be negligible from 
data that we have generated/published from a series of 
trials using similar standardised interventions. Our recent 
trials of hand exercises in rheumatoid arthritis and CB 
interventions in low back pain generated an intracluster 
correlation (ICC) of less than 0.0001.54 55 We anticipate 
about 20 therapists delivering the intervention, treating 
an average of 12–15 participants each. We have not incor-
porated a formal inflation for a therapist effect as the loss 
to follow-up allowance is generous and should mitigate 
against any moderate to large therapist effects.
The sample size is a minimum of 402 participants and 
a maximum of 540, to be finalised following a review of 
the sample size assumptions (in particular any evidence 
of clustering or a larger baseline SD) by the DMEC. A 
number of assumptions in the sample size estimate will be 
checked at this interim time point and adaptations made 
if needed, including the baseline SD of the ODI and the 
observed ICC. The DMEC will review these assumptions 
at this time point and make recommendations regarding 
the final sample size to the Trial Management Group and 
Programme Steering Committee (PSC). No interim anal-
ysis of the primary outcome will be performed.
Analysis
Data will be reported in accordance with the Consoli-
dated Standards of Reporting Trials guidelines for RCTs 
and the appropriate extensions.56 A final statistical anal-
ysis plan will be developed by the end of the recruitment 
period, and we provide an outline description here. The 
primary analysis will be ‘intention to treat’, where partici-
pants will be included in their randomised groups. Effect 
estimates together with their 95% CIs will be reported. 
The primary outcome, ODI at 12 months, will be analysed 
using a linear multivariable regression multilevel method 
to take account of any therapist effect and adjusted for the 
region, baseline ODI score, stratification and important 
prognostic variables.
Missing data will be minimised by careful data manage-
ment and training. The nature and mechanism for 
missing variables and outcomes will be investigated, and if 
appropriate multiple imputation will be used. Sensitivity 
analyses will be undertaken, assessing the underlying 
missing data assumptions.
A secondary complier average causal effect (CACE) anal-
ysis57 will explore the effect of adherence with the inter-
vention (attendance and the participants’ engagement 
with the programme rated by the physiotherapist).58 For 
the purposes of the primary CACE analysis, we will define 
adherence as attending at least 9 out of the 12 sessions 
(75%). This would ensure that the majority of educa-
tional/discussion content is delivered. No one session 
is considered more important than another regarding 
educational/discussion content. Core CB concepts are 
introduced during the earlier sessions and are reiterated 
during subsequent sessions so attendance at nine sessions 
would ensure all core content is covered. Attendance at 
nine sessions will ensure that the participant is introduced 
to the home exercise programme and has undertaken the 
exercise programme for a minimum of 6 weeks (sessions 
1–9 are delivered over a 6-week period). Six weeks of 
strength training has been shown to be sufficient to result 
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in short-term improvements in muscle strength and phys-
ical function.59–61
We have also defined a priori subgroup criteria based on 
the published literature and will explore treatment effects 
by age (65–74 years/75+ years), gender (male/female), 
Tilburg Frailty Index scores (0–4/5+),37 Fear Avoidance 
Beliefs Questionnaire scores (0–14/15+),62 STarT Back 
Risk Stratification score (low-risk/medium-risk/high-
risk groups),21 hand grip strength (men: <30/30+; 
women <20/20+)63 and SPPB scores (SPPB 0–6 low perfor-
mance; SPPB 7–9 intermediate performance; SPPB 10–12 
high performance63). Among participants who have an 
MRI scan prior to randomisation, we will estimate treat-
ment effects in two subgroups defined by MRI parameters 
(cross-sectional spinal canal area cut-point of 100 mm2).26 
Subgroup effects will be analysed using interaction with 
treatment tests and will be displayed using forest plots.64
We will carry out a series of additional exploratory 
subgroup and interaction analyses to identify other MRI 
scan parameters and baseline factors that predict change 
in ODI scores between baseline and 12 months. Inter-
action and polynomial terms will be considered when 
carrying out the exploratory analysis, and the analyses 
may be based on continuous or binary cut-points. These 
models will report variables that predict the outcome at 
12 months with 95% CIs and p value. These additional 
analyses will be presented in secondary publications and 
with appropriate caveats about the interpretation of 
exploratory subgroup analyses.
Further supplementary analysis may include mediation 
analysis to evaluate treatment mechanisms, and explor-
atory analyses of exercise dose effects including profiling 
of treatment response trajectories. These are a priori 
analyses based on the logic model used to develop the 
intervention, and will examine (1) whether the interven-
tion affects the hypothesised mediators as intended, (2) 
whether changes in the hypothesised mediators relate 
to changes in outcomes, and (3) whether the effects of 
the intervention on the outcomes are attributable to 
changes in the hypothesised causal pathway.
Economic evaluation
A prospective economic evaluation, conducted from an 
NHS and personal social services perspective, is inte-
grated into the trial design. The economic evaluation will 
estimate the difference in the cost of resources used by 
participants in the two arms of the trial, enabling costs and 
consequences to be compared between alternative forms 
of physiotherapy. The economic assessment method will 
adhere to the recommendations of the National Institute 
for Health and Care Excellence Reference Case.65
We will estimate the costs of delivering the intervention, 
including development and training, the cost of deliv-
ering sessions, and participant follow-up/management. 
Broader resource utilisation is captured through two 
principal sources: (1) participant interview administered 
at 6 and 12 months postrandomisation and (2) routine 
health service data collection systems (Hospital Episode 
Statistics). Unit costs for health and social care resources 
will be derived from local and national sources.66 Costs 
will be standardised to current prices where possible. 
Health-related quality of life will be measured at base-
line and at 6 and 12 months postrandomisation using 
the generic EuroQol EQ-5D-5L; national tariff sets will be 
used to generate quality-adjusted life-years (QALYs).67–69 
We will in the first instance use self-report of the EuroQol 
EQ-5D-5L measure. Multiple imputation methods will be 
used to impute missing data and avoid biases associated 
with complete case analysis.70 The results of the economic 
evaluation will be expressed in terms of incremental cost 
per QALY gained. Non-parametric bootstrap estimation 
will be used to derive 95% CIs for the mean cost and 
QALY differences between the trial groups, as well as to 
populate a cost-effectiveness plane. A series of sensitivity 
analyses will be undertaken to explore the implications 
of uncertainty on the incremental cost-effectiveness ratios 
and to consider the broader issue of the generalisability 
of the study results. The full details of the economic eval-
uation will be described in the health economic analysis 
plan.
Qualitative study
The aim of the qualitative study is to better understand 
participant experiences both of living and ageing with 
NC, and their experience of the interventions delivered 
during the trial. Understanding the experiences of the 
participants will inform strategies for implementation if 
the intervention is clinically effective.
All participants recruited to the trial are eligible. As 
part of the consent process for the trial, participants are 
informed about the interview study and asked if they are 
willing to be contacted by a researcher to receive more 
information. Participants who agree are provided with an 
additional information sheet and contacted by the qual-
itative research team. Prior to starting the first interview, 
written consent is sought. Consent is reaffirmed verbally 
prior to each follow-up telephone interview.
We are interviewing participants at three time points 
over the course of the trial in order to capture physical, 
psychological, social and contextual changes. Topics 
explored include current impact of NC on day-to-day 
life and well-being, beliefs about the role of exercise in 
ameliorating symptoms, the role of exercise on slowing/
reversing physical decline, and how these beliefs impact 
on adherence to the treatments.
We estimate 60 participants will be required to ensure 
data saturation is reached in all three interviews while 
ensuring diversity of participants by age, gender, ethnicity 
and intervention arm, allowing for attrition over the 
course of the study.71 72 In any one recruitment site 
interview participants are recruited consecutively, and 
as recruitment proceeds sampling is adjusted to ensure 
diversity of age, gender, ethnicity and intervention arm.
Interviews are semistructured using prespecified open-
ended questions. The interviewer uses prompts to further 
investigate responses and allows the participant to explore 
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topics they feel are relevant.71 73 The first interview takes 
place at a location convenient to the participant, usually 
their home. The second and third interviews are tele-
phone interviews to reduce resource implications for the 
project. However, if a telephone conversation is unfea-
sible (eg, poor hearing), then subsequent interviews are 
conducted face to face.
The first interview takes place between randomisation 
and starting treatment. Participants do not yet know their 
treatment allocation. Questions focus on the impact of 
NC on the participant’s physical and psychosocial health, 
their beliefs around exercise and ageing, and concerns 
and hopes regarding the intervention. The interview 
takes up to 90 min and is audio-recorded.
The second interview is approximately 1 month after 
completing treatment. Topics explored include the 
participant’s experiences of the intervention, adherence 
to home exercises, and any changes in their symptoms, 
exercise and ageing beliefs, physical activity levels, or 
life circumstances. The third interview coincides with 
the 12-month follow-up assessment and further explores 
these topics, and how they may have changed after an 
extended period of self-management. Interview sched-
ules are adapted to account for data captured in earlier 
interviews, and the interviewer has access to the outcome 
measures for each interviewee for exploration during the 
interview. The telephone interviews are recorded, and 
notes are transcribed by the interviewer from the audio 
recordings.
Audio recordings of first interviews are transcribed 
verbatim by an independent transcriber, anonymised and 
allocated an ID number. The telephone interview notes 
are checked against the audio recordings and linked to 
the first interview through the ID number. Participants 
are sent a copy of the transcripts if requested, and may 
delete any information they would not like to be used.
All transcripts are imported into NVivo and analysed 
using thematic analysis.74 Coding is undertaken as each 
transcript is received. We will undertake cross-case anal-
ysis.75 To understand trajectories of change in relation to 
back pain and NC, we will undertake longitudinal case 
comparative analysis, an approach to analysis used previ-
ously by the research team.76
trial management
This trial is run by a UKCRC fully registered clinical trials 
unit, according to approved and audited standard oper-
ating procedures. All trial staff undergo regular training 
to ensure they are compliant with Good Clinical Practice 
and other relevant legislation and the requirements such 
as the Data Protection Act.
data management and checking
All data are processed according to the Data Protection 
Act 1998 and all documents are stored safely in confi-
dential conditions. Each participant is provided with 
a unique trial identification number. Data are entered 
manually onto the trial database (OpenClinica). The 
BOOST Trial Office reviews all data collection forms for 
completeness and accuracy using automated validation 
checks, querying missing and nonsensical data with sites, 
according to trial-specific procedures which have been 
developed to ensure data quality.
Patient and public involvement
During the application process for this trial, we assembled 
a patient and public involvement (PPI) group and we 
have continued to work closely with them. JuF is the lead 
PPI representative and a coapplicant and contributed to 
the design of the trial. We appointed a PPI representative 
to be an independent member of the PSC. PPI engage-
ment has been undertaken in face-to-face meetings and 
via emails and phone calls to make it as convenient as 
possible for the PPI group to contribute. PPI represen-
tatives have assisted with the development of the physio-
therapy intervention. Two PPI representatives attended 
the intervention development day along with clinicians 
and researchers. One PPI representative carried out the 
proposed exercise programme in her home so she could 
give feedback on the practicalities of performing the 
proposed programme. PPI representatives helped us to 
develop the patient materials for the intervention.
PILs, consent forms and posters advertising the trial 
have been reviewed by the PPI group and they have 
provided feedback on the layout and wording. We have 
piloted questionnaires with our PPI group. PPI represen-
tatives have helped with developing interview schedules 
for the qualitative study, and we have carried out some 
practice interviews with the PPI representatives prior to 
undertaking the actual study.
EthICs And dIssEMInAtIon
Site-specific approvals were provided by the NHS Research 
and Development Departments at each participating site. 
The Chief Investigator will submit and, where necessary, 
obtain approval from the above parties for all substantial 
amendments to the original approved documents.
There were several ethical issues when designing this 
study. A study of older adults may identify individuals 
with previously unidentified cognitive impairment. As 
part of the screening process, participants complete the 
AMT. Individuals with a score of 6 or below (out of 10) 
are excluded as this suggests impaired cognitive func-
tion requiring further assessment.15–17 The researchers, 
conducting the eligibility screening, are trained to deal 
with this and to recommend that the person visit their GP 
to for further assessment.
The study screening procedures may identify individ-
uals who have signs of serious spinal pathology (eg, cauda 
equina syndrome). In this case, the researcher would 
discuss it with the participant and as soon as possible with 
the local principal investigator and/or patient’s spinal 
consultant or GP and take appropriate action.
Some participants will undergo an MRI scan as a 
research investigation. Some participants may want the 
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results of their scan. However, as participants would not 
have had access to a scan as part of their routine NHS 
care, we will only make results available at the end of 
the trial unless we detect a serious spinal pathology (eg, 
spinal malignancy). In this situation, the participant’s 
GP or spinal consultant will be informed immediately. If 
we were to provide the scan results, this may influence 
the beliefs of participants and their clinicians about 
the value of different treatments. This process is made 
clear to potential participants during the recruitment 
and consent procedures so participants understand the 
purpose of the MRI scan.
The PSC provides overall supervision of this research on 
behalf of the funder. It comprised the Chief Investigator, 
Project Lead, Trial Manager, Statistician and four inde-
pendent members (including the committee chair). The 
PSC monitors trial progress and conduct and provides 
expert advice. In addition, a DMEC has been appointed. 
The DMEC consists of three independent experts with 
relevant clinical research and statistical experience. The 
DMEC has adopted the DAta MOnitoring Committees: 
Lessons, Ethics, Statistics (DAMOCLES) charter,77 which 
defines its terms of reference and operation in relation 
to oversight of the trial. No interim outcome analysis is 
planned. Direct access to research data will be granted 
to authorised representatives of the Sponsor (University 
of Oxford), regulatory authorities or the host institution 
for monitoring and/or auditing of the study to ensure 
compliance with regulations.
The results will be published in a peer-reviewed journal 
and at conferences, as well as in a report to the funder. 
A plain English summary will be made available on the 
BOOST website for participants (https:// boost. octru. ox. 
ac. uk/).
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